As with the results obtained with IL-18 and PD-1 co-blocking treatment, combining PD-1 and CXCR4 blocking increased CD8+ T-cell infiltration of the tumors and enhanced the survival of the tumor-bearing mice [121]. Here, CXCR4 is linked to neoplasm.